The Translational Research Institute
UQDI has been part of the Translational Research Institute since late 2012. TRI is an Australian-first and will see Australia play a leading role in international efforts to address infectious disease, cancer and diabetes.
As one of the southern hemisphere's largest facilities of its kind, TRI is one of only a few places worldwide where new biopharmaceuticals and treatments can be researched, discovered, manufactured, and clinically tested in one location. The Translational Research Institute - ‘translating laboratory success into benefits for patients’ - is a major step forward in growing Australia’s research capacity.
The TRI building will house up to 900 researchers and support staff. State of the art facilities includes physical containment level 2 (PC2) and level 3 (PC3) laboratories, a vivarium, a Cell Therapies clean room facility, staff support spaces, a large lecture theatre and advanced education facilities. The associated and adjacent biopharmaceuticals facility houses a pilot drug manufacturing facility to bring discoveries to pilot commercialisation.
TRI is a joint venture involving The University of Queensland, Queensland University of Technology Institute for Biomedical Innovation, the Princess Alexandra Hospital, Mater Medical Research Institute and the Queensland Government. TRI is the vision of 2006 Australian of the Year, Professor Ian Frazer, and supported by $354m in grants and funding from the Australian Government, Queensland Government and Atlantic Philanthropies.
For further information about TRI, please visit www.tri.edu.au